TLX
Telix
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About TLX
Telix Pharmaceuticals Limited
A commercial biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic ("therapeutic diagnostics") radiopharmaceuticals
Pharmaceutical
01/03/2017
11/13/2024
NASDAQ Stock Exchange
535
12-31
Depository Receipts (Ordinary Shares)
55 Flemington Road, North Melbourne, Victoria 3051, Australia
Development and commercialization of molecularly targeted radiological products for the treatment of cancer
Telix Pharmaceuticals Limited was incorporated in Australia on January 3, 2017. The Company is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. Their mission is to become a global leader in radiopharmaceuticals, combining treatment and diagnosis for the benefit of patients, an innovative precision medicine concept often referred to as "therapeutic diagnostics. ". They have an extensive pipeline of therapeutic radiopharmaceutical candidates with a focus on urological oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Their treatment approach aims to combine imaging and treatment to "observe and treat" cancer and rare diseases, better enabling patients to make treatment decisions and personalize treatment.
Company Financials
Revenue & Expenses
TLX has released its 2024 Q2 earnings report, with revenue of 126.17M, reflecting a YoY change of 58.39%, and net profit of 7.80M, showing a YoY change of 300.83%. The Sankey diagram below clearly presents TLX’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
